Big Pharma Helps Pour $900m Into Grail
Executive Summary
The biggest venture funding round in history, pan-cancer screening test developer Grail has reeled in $900m in the first close of what it hopes will be a $1bn Series B round.
Topics
- Device Areas
- Cancer
- In Vitro Diagnostics
- Subjects
- Financing
- Deals
- Commercial
- StartUps and SMEs
- Industries
- Medical Device
Latest Headlines
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
MT104520
Ask The Analyst
Ask the Analyst is free for subscribers. Submit your question and one of our analysts will be in touch.
Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.
All fields are required.
MT104520
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.